Neal D. Shore, MD, FACS, discusses the results of the retrospective review on real-world patterns of genomic testing in patients with metastatic castration-resistant prostate cancer.
Neal D. Shore, MD, FACS, medical director and certified physician investigator at the Carolina Urologic Research Center, discusses the results of the retrospective review on real-world patterns of genomic testing in patients with metastatic castration-resistant prostate cancer (mCRPC).
Patients being seen in the community setting made up about 90% of the Flatiron database population used in this analysis, while the other 10% were in the academic setting. Shore and his colleagues looked at about 5000 patients over a several-year period. He says they found that the incidence of patients who were tested in 2013 came to 0% and raised to about 11% by 2018.
Other databases show that the likelihood of homologous recombination repair alteration is about 25% to 30%, which shows a discrepancy in the rate of testing to how many patients are likely to have this alteration, according to Shore. He and his colleagues broke down the most commonly tested gene alterations such as BRCA1/2, ATM, PALB2, FANCA, and CDK12.
This retrospective analysis of a large registry shows that physicians in this field need further education, especially since these alterations have 2 actionable PARP inhibitors approved as of this year, Shore explains.
<< View more resources and information regarding prostate cancer
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen